Medical device manufacturer Masimo has initiated legal action against U.S. Customs and Border Protection regarding Apple Watch Blood Oxygen functionality. The company disputes CBP's decision to allow Apple's recent workaround implementation through iOS 18.6.1. Masimo argues that customs officials exceeded their regulatory authority when approving the feature's return. The legal challenge seeks restoration of original import restrictions on affected Apple Watch models. This dispute stems from a December 2023 International Trade Commission ruling finding Apple violated Masimo's pulse oximetry patents.
The ITC initially banned imports of Apple Watch Series 9 and Ultra 2 devices containing the contested technology. Apple responded by temporarily removing the Blood Oxygen feature through software updates to continue sales. CBP reversed its position on August 1, 2025, permitting the feature's return without notifying Masimo. The medical company discovered this change on August 14 when Apple announced the functionality's restoration. Masimo contends this reversal undermines patent protections.
The ITC initially banned imports of Apple Watch Series 9 and Ultra 2 devices containing the contested technology. Apple responded by temporarily removing the Blood Oxygen feature through software updates to continue sales. CBP reversed its position on August 1, 2025, permitting the feature's return without notifying Masimo. The medical company discovered this change on August 14 when Apple announced the functionality's restoration. Masimo contends this reversal undermines patent protections.
